Juliette Mazereeuw-Hautier

France

Publications
  • Mini Review   
    Dupilumab: Breaking Boundaries beyond the Barriers of Atopy
    Author(s): Sara A. Altandi, Maella Severino-Freire, Juliette Mazereeuw-Hautier

    Dupilumab is a monoclonal antibody that blocks the effects of interleukin-4 and interleukin-13 thereby inhibiting Th2-mediated inflammation. It is approved for moderate-to-severe atopic dermatitis requiring systemic treatment. It was expanded to off-label treatment of numerous dermatological conditions. We provide an update on the increasing scope of uses of dupilumab in rare and common dermatological diseases refractory to frontline therapy. PubMed/MEDLINE database were searched for articles mentioning the term 'dupilumab', excluding the terms “atopic dermatitis”, “asthma” and “nasal polyps”, then manually reviewed to identify published data on the off-label dermatologic uses of dupilumab that were not mentioned in previous reviews. Dupilumab appears to be an effective treatment for several dermatologic conditions including congenital ichth.. View more»

    DOI: 10.35248/2155-6121.22.13.286

    Abstract HTML PDF